Clopidogrel — BrandWiki

Clopidogrel

verifiedrevid	460044539
width	200
alt	Skeletal formula
image2	Clopidogrel molecule ball from xtal.png
width2	200
alt2	Ball-and-stick model clopidogrel
pronounce	‡R1R‡
tradename	Plavix, Iscover, others
medlineplus	a601040
dailymedid	Clopidogrel
pregnancy au	B1
routes of administration	By mouth
atc prefix	B01
atc suffix	AC04
legal au	S4
legal uk	POM
legal uk comment	‡R2R‡
legal us	Rx-only
legal us comment	‡R3R‡
legal eu	Rx-only
legal eu comment	‡R4R‡‡R5R‡
bioavailability	>50%
protein bound	94–98%
metabolism	Liver
onset	2 hours
elimination half-life	7–8 hours (inactive metabolite)
duration of action	5 days
excretion	50% Kidney 46% bile duct
cas number	113665-84-2
pubchem	60606
iuphar ligand	7150
drugbank	DB00758
chemspiderid	54632
unii	A74586SNO7
kegg	D07729
kegg2	D00769
chebi	37941
chembl	1771
pdb ligand	CGE
iupac name	(+)-(S)-methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate
c	16
h	16
cl	1
n	1
o	2
s	1
smiles	COC(=O)[C@H](c1ccccc1Cl)N2CCc3c(ccs3)C2
stdinchi	1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
stdinchikey	GKTWGGQPFAXNFI-HNNXBMFYSA-N

Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). It is taken by mouth. Its effect starts about two hours after intake and lasts for five days.[6]

Common side effects include headache, nausea, easy bruising, itching, and heartburn.[6] More severe side effects include bleeding and thrombotic thrombocytopenic purpura.[6] While there is no evidence of harm from use during pregnancy, such use has not been well studied.[7] Clopidogrel is in the thienopyridine-class of antiplatelets.[6]

Medical uses

Clopidogrel is used to prevent heart attack and stroke in people who are at high risk of these events, including those with a history of myocardial infarction and other forms of acute coronary syndrome, stroke, and those with peripheral artery disease.

Treatment with clopidogrel or a related drug is recommended by the American Heart Association and the American College of Cardiology for people who:

It is also used, along with acetylsalicylic acid (ASA, aspirin), for the prevention of thrombosis after placement of a coronary stent[15] or as an alternative antiplatelet drug for people intolerant to aspirin.[16] It is available as a fixed-dose combination with aspirin.[17]

A meta-analysis found clopidogrel's benefit as an antiplatelet drug in reducing cardiovascular death, myocardial infarction, and stroke to be 25% benefit in smokers, with little (8%) benefit in non-smokers.[18]

Consensus-based therapeutic guidelines also recommend the use of clopidogrel rather than aspirin (ASA) for antiplatelet therapy in people with a history of gastric ulceration, as inhibition of the synthesis of prostaglandins by ASA can exacerbate this condition. In people with healed ASA-induced ulcers, however, those receiving ASA plus the proton-pump inhibitor (PPI) esomeprazole had a lower incidence of recurrent ulcer bleeding than those receiving clopidogrel.[19] However, prophylaxis with proton-pump inhibitors along with clopidogrel following acute coronary syndrome may increase adverse cardiac outcomes, possibly due to inhibition of CYP2C19, which is required for the conversion of clopidogrel to its active form.[20][21][22] The European Medicines Agency has issued a public statement on a possible interaction between clopidogrel and proton-pump inhibitors.[23] However, several cardiologists have voiced concern that the studies on which these warnings are based have many limitations and that it is not certain whether an interaction between clopidogrel and proton-pump inhibitors is real.[24]

Present for treatment with a myocardial infarction with ST-elevation[12]
A loading dose given in advance of percutaneous coronary intervention (PCI), followed by a full year of treatment for those receiving a vascular stent
A loading dose given in advance of fibrinolytic therapy, continued for at least 14 days
Present for treatment of a non-ST elevation myocardial infarction or unstable angina[13]
Including a loading dose and maintenance therapy in those receiving PCI and unable to tolerate aspirin therapy
Maintenance therapy for up to 12 months in those at medium to high risk for which a noninvasive treatment strategy is chosen
In those with stable ischemic heart disease, treatment with clopidogrel is described as a "reasonable" option for monotherapy in those who cannot tolerate aspirin, as is treatment with clopidogrel in combination with aspirin in certain high risk patients.[14]

Pharmacology

Clopidogrel is a prodrug which is metabolized by the liver into its active form. The active form specifically and irreversibly inhibits the P2Y12 subtype of ADP receptor, which is important in activation of platelets and eventual cross-linking by the protein fibrin.

Pharmacokinetics and metabolism

After repeated oral doses of 75 mg of clopidogrel (base), plasma concentrations of the parent compound, which has no platelet-inhibiting effect, are very low and, in general, are below the quantification limit (0.258 μg/L) beyond two hours after dosing.

Clopidogrel is a prodrug, which is activated in two steps, first by the enzymes CYP2C19, CYP1A2, and CYP2B6, then by CYP2C19, CYP2C9, CYP2B6, and CYP3A.[35] The thiophene ring is converted to a thiolactone. This thiolactone is then oxidized by a cytochrome P450 into a thiolactone S-oxide, that is unstable and opens in water to a sulfenic acid. In presence of cell reductants (glutathione or ascorbic acid or enzymatically) the sulfenic acid is reduced to the active thiol metabolite.[36]. The active metabolite has three sites that are stereochemically relevant, making a total of eight possible isomers. These are: a stereocentre at C4 (attached to the —SH thiol group), a double bond at C3—C16, and the original stereocentre at C7. Only one of the eight structures is an active antiplatelet drug. This has the following configuration: Z configuration at the C3—C16 double bond, the original S configuration at C7,[34] and, although the stereocentre at C4 cannot be directly determined, as the thiol group is too reactive, work with the active metabolite of the related drug prasugrel suggests the R-configuration of the C4 group is critical for P2Y12 and platelet-inhibitory activity.

The active metabolite has an elimination half-life of about 0.5 to 1.0 h, and acts by forming a disulfide bridge with the platelet ADP receptor. Patients with a variant allele of CYP2C19 are 1.5 to 3.5 times more likely to die or have complications than patients with the high-functioning allele.[37][38][39]

Following an oral dose of 14C-labeled clopidogrel in humans, about 50% was excreted in the urine and 46% in the feces in the five days after dosing.[6]

Clopidogrel and the main circulating metabolite bind reversibly in vitro to human plasma proteins (98% and 94%, respectively). The binding is not saturable in vitro up to a concentration of 110 μg/mL.

In 2010, the US Food and Drug Administration (FDA) added a boxed warning, later updated, to Plavix, alerting that the drug can be less effective in people unable to metabolize the drug to convert it to its active form.[40]

Effect of food: Administration of clopidogrel bisulfate with meals did not significantly modify the bioavailability of clopidogrel as assessed by the pharmacokinetics of the main circulating metabolite.
Absorption and distribution: Clopidogrel is rapidly absorbed after oral administration of repeated doses of 75-milligram clopidogrel (base), with peak plasma levels (about 3 mg/L) of the main circulating metabolite occurring around one hour after dosing. The pharmacokinetics of the main circulating metabolite are linear (plasma concentrations increased in proportion to dose) in the dose range of 50 to 150 mg of clopidogrel. Absorption is at least 50% based on urinary excretion of clopidogrel-related metabolites.

Metabolism and elimination: In vitro and in vivo, clopidogrel undergoes rapid hydrolysis into its carboxylic acid derivative. In plasma and urine, the glucuronide of the carboxylic acid derivative is also observed.

Pharmacogenetics

CYP2C19 is an important drug-metabolizing enzyme that catalyzes the biotransformation of many clinically useful drugs, including antidepressants, barbiturates, proton-pump inhibitors, and antimalarial and antitumor drugs. Clopidogrel is one of the drugs metabolized by this enzyme.[6]

The US Food and Drug Administration (FDA) added a boxed warning on clopidogrel in 2010 about CYP2C19-poor metabolizers.[40] People with variants in cytochrome P-450 2C19 (CYP2C19) have lower levels of the active metabolite of clopidogrel, less inhibition of platelets, and a 3.58-times greater risk for major adverse cardiovascular events such as death, heart attack, and stroke; the risk was greatest in CYP2C19 poor metabolizers.[26][41]

A published review showed that some mutations of CYP2C19, CYP3A4, CYP2C9, CYP2B6, and CYP1A2 genes could affect the clinical efficacy and safety of clopidogrel treatment. For instance, patients carrying the mutations CYP2C19*2, CYP2C19*3, CYP2C9*2, CYP2C9*3, and CYP2B6*5 alleles may not respond to clopidogrel due to poor platelet inhibition efficacy revealed among them.[42]

Mechanism of action

The active metabolite of clopidogrel specifically and irreversibly inhibits the P2Y12 subtype of ADP receptor, which is important in activation of platelets and eventual cross-linking by the protein fibrin.[35] Platelet inhibition can be demonstrated two hours after a single dose of oral clopidogrel, but the onset of action is slow, so a loading dose of either 600 or 300 mg is administered when a rapid effect is needed.[43]

Society and culture

Economics

Plavix is marketed worldwide in nearly 110 countries, with sales of US$6.6 billion in 2009.[44] It was the second-top-selling drug in the world in 2007[45] and was still growing by over 20% in 2007. US sales were US$4.9 billion in 2008.[46]

Before the expiry of its patent, clopidogrel was the second best-selling drug in the world. In 2010, it grossed over US$9 billion in global sales.[47]

In 2006, generic clopidogrel was briefly marketed by Apotex, a Canadian generic pharmaceutical company before a court order halted further production until resolution of a patent infringement case brought by Bristol-Myers Squibb.[48] The court ruled that Bristol-Myers Squibb's patent was valid and provided protection until November 2011.[49] The FDA extended the patent protection of clopidogrel by six months, giving exclusivity that would expire in May 2012.[50] The FDA approved generic versions of clopidogrel in May 2012.[51]

Names

Generic clopidogrel is marketed by many companies worldwide under many brand names.

As of, brands included Aclop, Actaclo, Agregex, Agrelan, Agrelax, Agreless, Agrelex, Agreplat, Anclog, Angiclod, Anplat, Antiagrex, Antiban, Antigrel, Antiplaq, Antiplar, Aplate, Apolets, Areplex, Artepid, Asogrel, Atelit, Atelit, Ateplax, Atervix, Atheros, Athorel, Atrombin, Attera, Bidogrel, Bigrel, Borgavix, Carder, Cardogrel, Carpigrel, Ceraenade, Ceruvin, Cidorix, Clatex, Clavix, Clentel, Clentel, Clidorel, Clodel, Clodelib, Clodian, Clodil, Cloflow, Clofre, Clogan, Clogin, Clognil, Clogrel, Clogrelhexal, Clolyse, Clont, Clood, Clopacin, Clopcare, Clopeno, Clopex Agrel, Clopez, Clopi, Clopid, Clopida, Clopidep, Clopidexcel, Clopidix, Clopidogrel, Clopidogrelum, Clopidomed, Clopidorex, Clopidosyn, Clopidoteg, Clopidowel, Clopidra, Clopidrax, Clopidrol, Clopigal, Clopigamma, Clopigrel, Clopilet, Clopimed, Clopimef, Clopimet, Clopinovo, Clopione, Clopiright, Clopirite, Clopirod, Clopisan, Clopistad, Clopistad, Clopitab, Clopithan, Clopitro, ClopiVale, Clopivas, Clopivaz, Clopivid, Clopivin, Clopix, Cloplat, Clopra, Cloprez, Cloprez, Clopval, Clorel, Cloriocard, Cloroden, Clotix, Clotiz, Clotrombix, Clova, Clovas, Clovax, Clovelen, Clovex, Clovexil, Clovix, Clovvix, Copalex, Copegrel, Copidrel, Copil, Cordiax, Cordix, Corplet, Cotol, CPG, Cugrel, Curovix, Dapixol, Darxa, Dasogrel-S, Dclot, Defrozyp, Degregan, Deplat, Deplatt, Diclop, Diloxol, Dilutix, Diporel, Doglix, Dogrel, Dogrel, Dopivix, Dorel, Dorell, Duopidogrel, DuoPlavin, Eago, Egitromb, Espelio, Eurogrel, Expansia, Farcet, Flucogrel, Fluxx, Freeclo, Globel, Glopenel, Grelet, Greligen, Grelix, Grepid, Grepid, Grindokline, Heart-Free, Hemaflow, Hyvix, Idiavix, Insigrel, Iscover, Iskimil, Kafidogran, Kaldera, Kardogrel, Karum, Kerberan, Keriten, Klepisal, Klogrel, Klopide, Klopidex, Klopidogrel, Klopik, Klopis, Kogrel, Krossiler, Larvin, Lodigrel, Lodovax, Lofradyk, Lopigalel, Lopirel, Lyvelsa, Maboclop, Medigrel, Miflexin, Mistro, Mogrel, Monel, Monogrel, Moytor, Myogrel, Nabratin, Nadenel, Nefazan, Niaclop, Nivenol, Noclog, Nofardom, Nogreg, Nogrel, Noklot, Norplat, Novigrel, Oddoral, Odrel, Olfovel, Opirel, Optigrel, Panagrel, Pedovex, Pegorel, Piax, Piclokare, Pidgrel, Pidogrel, Pidogul, Pidovix, Pigrel, Pingel, Placta, Pladel, Pladex, Pladogrel, Plagerine, Plagrel, Plagril, Plagrin, Plahasan, Plamed, Planor, PlaquEx, Plasiver, Plataca, Platarex, Platec, Platel, Platelex, Platexan, Platil, Platless, Platogrix, Platrel, Plavedamol, Plavicard, Plavictonal, Plavidosa, Plavigrel, Plavihex, Plavitor, Plavix, Plavocorin, Plavogrel, Plavos, Pleyar, Plogrel, Plvix, Pravidel, Pregrel, Provic, Psygrel, Q.O.L, Ravalgen, Replet, Respekt, Revlis, Ridlor, Roclas, Rozak, Sanvix, Sarix, Sarovex, Satoxi, Shinclop, Sigmagrel, Simclovix, Sintiplex, Stazex, Stroka, Stromix, Sudroc, Synetra, Talcom, Tansix, Tessyron, Thinrin, Throimper, Thrombifree, Thrombo, Timiflo, Tingreks, Torpido, Triosal, Trogran, Troken, Trombex, Trombix, Tuxedon, Unigrel, Unplaque, Vaclo, Vasocor, Vatoud, Venicil, Vidogrel, Vivelon, Vixam, Xydrel, Zakogrel, Zillt, Zopya, Zylagren, Zyllt, and Zystol.

References

Clopidogrel Lexico Dictionaries, retrieved 26 October 2019^
Plavix Summary of Product Characteristics (SmPC) (emc), 23 January 2023, retrieved 15 January 2024^
Plavix- clopidogrel tablet, film coated DailyMed, 22 September 2022, retrieved 15 January 2024^
Plavix EPAR European Medicines Agency (EMA), 14 July 1998, retrieved 15 January 2024^
Iscover EPAR European Medicines Agency (EMA), 14 July 1998, retrieved 15 August 2024^
Clopidogrel Bisulfate The American Society of Health-System Pharmacists, retrieved 8 December 2016^
Clopidogrel (Plavix) Use During Pregnancy Drugs.com, retrieved 14 December 2016^
Analogue-based Drug Discovery John Wiley & Sons, 2006^
The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) World Health Organization, 2023^
Top 300 of 2023 ClinCalc, retrieved 12 August 2025^
Clopidogrel Drug Usage Statistics, United States, 2013 - 2023 ClinCalc, retrieved 18 August 2025^
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J. Am. Coll. Cardiol., January 2013^
2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation, August 2012^
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, December 2012^
Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3^
Michael D Randall; Karen E Neil (2004). Disease management. 2nd ed. London: Pharmaceutical Press. 159.^
DuoPlavin EPAR European Medicines Agency (EMA), 17 September 2018, retrieved 21 August 2020^
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (Clinical Research Ed.), 17 September 2013^
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding N. Engl. J. Med., 2005^
Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence Indian Journal of Pharmacology, 2011^
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome Journal of the American Medical Association, 2009^
Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor Arch Intern Med, April 2010^
Public statement on possible interaction between clopidogrel and proton pump inhibitors retrieved 31 March 2011^
EMEA issues warning on possible clopidogrel-PPI interaction, but is there really a problem? retrieved 31 March 2011^
Clopidogrel-Associated TTP An Update of Pharmacovigilance Efforts Conducted by Independent Researchers, Pharmaceutical Suppliers, and the Food and Drug Administration Stroke, 2004^
Plavix- clopidogrel bisulfate tablet, film coated DailyMed, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, 17 May 2019, retrieved 26 December 2019^
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial The Lancet, 2004^
Austria-Codex Österreichischer Apothekerverlag, 2007^
FDA Warns Plavix Patients of Drug Interactions WebMD, 23 February 2016, retrieved 23 November 2009^
Public Health Advisory: Updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC) Food and Drug Administration (FDA), 17 November 2009, retrieved 13 March 2010^
Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016 Eur. J. Clin. Pharmacol., February 2019^
Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update Drug Safety, 2014^
Current Oral Antiplatelets: Focus Update on Prasugrel The Journal of the American Board of Family Medicine, 2012^
Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab. Dispos., 2002^
Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? Journal of Thrombosis and Haemostasis, March 2012^
Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol, 20 February 2012^
Cytochrome p-450 polymorphisms and response to clopidogrel The New England Journal of Medicine, January 2009^
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events The New England Journal of Medicine, January 2009^
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study The Lancet, January 2009^
Safety announcement: Reduced effectiveness of Plavix in patients who are poor metabolizers U.S. Food and Drug Administration, 3 August 2017^
FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug U.S. Food and Drug Administration (FDA), 28 June 2019, retrieved 30 January 2022^
Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment Expert Opinion on Drug Metabolism & Toxicology, June 2021^
Clopidogrel^
New products and markets fuel growth in 2005 IMS Health, retrieved 2 March 2009^
Top Ten Global Products – 2007 IMS Health, 26 February 2008, retrieved 2 March 2009^
Justine Varieur Cadet. Strong Plavix sales pushes Bristol-Myers into the black for Q4 cardiovascularbusiness.com, 2009-02-04, retrieved 2026-01-08^
Catapulting clopidogrel pharmacogenomics forward Nature Medicine, January 2011^
Preliminary Injunction Against Apotex Upheld on Appeal Bristol-Myers Squibb, 8 December 2006, retrieved 14 March 2010^
U.S. judge upholds Bristol, Sanofi patent on Plavix Reuters, 19 June 2007, retrieved 5 September 2007^
FDA Gives Plavix a 6 Month Extension-Patent Now Expires on 17 May 2012 26 January 2011, retrieved 12 January 2012^
FDA approves generic versions of blood thinner Plavix U.S. Food and Drug Administration (FDA), 17 May 2012^
Clopidogrel International brand names Drugs.com, retrieved 1 April 2017^
Antiplatelet effects and pharmacodynamics of clopidogrel in cats J Am Vet Med Assoc, 2004^